{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Nkarta, Inc. technically bullish or bearish?
As of June 13, 2025, Nkarta, Inc. is in a mildly bearish trend, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.
Who are in the management team of Nkarta, Inc.?
As of March 2022, Nkarta, Inc.'s management team includes Dr. Ali Behbahani (Independent Chairman), Mr. Paul Hastings (CEO), and several independent directors: Dr. Tiba Aynechi, Mr. Fouad Azzam, Dr. Michael Dybbs, Dr. Simeon George, and Ms. Leone Patterson. The team features a blend of executive leadership and independent oversight.
What does Nkarta, Inc. do?
Nkarta, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf engineered natural killer cell therapies for cancer treatment. It has a market cap of approximately $128.43 million and reported a net profit loss of $32 million as of March 2025.
How big is Nkarta, Inc.?
As of Jun 18, Nkarta, Inc. has a market capitalization of 128.43 million and reported net sales of 0.00 million with a net profit of -111.24 million for the latest four quarters. As of Dec 24, the company has shareholder's funds of 407.98 million and total assets of 501.20 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
